Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCLVLF -0.51%85 3-Year Dividend Growth Rate is 7.70% as of Jun. 2026, which is 55% below its 10-year median of 17.00. GuruFocus rates CLVLF with a GF Score™ of 85/100 and a GF Value™ of $9.34 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 94 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 60.64% on this metric.
The historical rank and industry rank for Clinuvel Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:
CLVLF'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 7.7 Med: 17 Max: 26
Current: 7.7
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Clinuvel Pharmaceuticals was 26.00% per year. The lowest was 7.70% per year. And the median was 17.00% per year.
CLVLF's 3-Year Dividend Growth Rate is ranked better than 60.64% of 94
companies
in the Biotechnology industry
Industry Median: 5.4
vs CLVLF: 7.70
During the past 3 years, the average Dividends Per Share Growth Rate was 7.70% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 17.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Clinuvel Pharmaceuticals was 0.08. The lowest was 0.05. And the median was 0.07.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Clinuvel Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
AUD 0.050000
2026-09-03
2026-09-04
2026-09-18
Cash Dividend
annually
AUD:USD 0.710227
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Clinuvel Pharmaceuticals's Dividend Yield (%) for Today is calculated as
Current Share Price is $5.89.
Clinuvel Pharmaceuticals's Dividends per Share for the trailing twelve months (TTM) ended in Today is $0.03551135.
During the past 13 years, the highest Dividend Yield of Clinuvel Pharmaceuticals was 0.62%. The lowest was 0.05%. And the median was 0.14%.
Good Sign:
Clinuvel Pharmaceuticals Ltd stock Dividend Yield % is close to 10-year high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>
CLVLF vs VRTX, REGN, MRNA: 3-Year Dividend Growth Rate Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals 3-Year Dividend Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 7.70% mean?
Clinuvel Pharmaceuticals (CLVLF) has a 3-Year Dividend Growth Rate of 7.70% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 55% below median its historical median of 17.00. Over the past decade, Clinuvel Pharmaceuticals' 3-Year Dividend Growth Rate has ranged from 7.70 to 26.00. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #37 out of 94 companies in the Biotechnology industry, placing it in the top 39.4%.
Is Clinuvel Pharmaceuticals' 3-Year Dividend Growth Rate too high?
Clinuvel Pharmaceuticals' current 3-Year Dividend Growth Rate of 7.70% is 55% below median its 10-year median of 17.00. Over the past 10 years, this metric has ranged from a low of 7.70 to a high of 26.00. The Biotechnology industry median 3-Year Dividend Growth Rate is 5.40. Clinuvel Pharmaceuticals' value of 7.70% is 42.6% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #37 out of 94 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' 3-Year Dividend Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #37 out of 94 companies for 3-Year Dividend Growth Rate. This puts Clinuvel Pharmaceuticals in the upper half of its industry. The industry median 3-Year Dividend Growth Rate is 5.40. Clinuvel Pharmaceuticals' value of 7.70% is 42.6% above this benchmark. Historically, Clinuvel Pharmaceuticals' own 3-Year Dividend Growth Rate has ranged from 7.70 to 26.00 over the past decade. While the company's 10-year median is 17.00 vs. the industry median of 5.40, Clinuvel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Biotechnology company?
The median 3-Year Dividend Growth Rate among Biotechnology companies is 5.40, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current 3-Year Dividend Growth Rate of 7.70% is 42.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year Dividend Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current 3-Year Dividend Growth Rate is 7.70%, which is 55% below median its own 10-year median of 17.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.34, compared to a current price of $5.89 — trading 36.9% below its estimated fair value. The current 3-Year Dividend Growth Rate is 7.70%, which is 55% below median its 10-year median of 17.00 and 42.6% above the Biotechnology industry median of 5.40. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current 3-Year Dividend Growth Rate is 7.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $5.89 is trading 36.9% below its estimated GF Value™ of $9.34.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
3-Year Dividend Growth Rate: 7.70% (55% below median its 10-year median of 17.00)
GF Value™: $9.34 vs. price of $5.89 (36.9% below fair value)
Industry Position: 42.6% above the Biotechnology median (#37 of 94)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score
Get the complete analysis for CLVLF
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
